Your browser doesn't support javascript.
loading
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
San-Miguel, Jesús F; Echeveste Gutierrez, Maria-Asunción; Spicka, Ivan; Mateos, María-Victoria; Song, Kevin; Craig, Michael D; Bladé, Joan; Hájek, Roman; Chen, Christine; Di Bacco, Alessandra; Estevam, Jose; Gupta, Neeraj; Byrne, Catriona; Lu, Vickie; van de Velde, Helgi; Lonial, Sagar.
Afiliación
  • San-Miguel JF; Clinica Universidad de Navarra, Centro Investigación Medica Aplicada (CIMA), El Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain sanmiguel@unav.es.
  • Echeveste Gutierrez MA; Hospital Universitario Donostia, San Sebastián, Spain.
  • Spicka I; 1Medical Department - Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic.
  • Mateos MV; Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Spain.
  • Song K; Division of Hematology, University of British Columbia, Vancouver, BC, Canada.
  • Craig MD; Department of Medicine, West Virginia University, Morgantown, WV, USA.
  • Bladé J; Department of Hematology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain.
  • Hájek R; Department of Haematooncology, University Hospital Ostrava, Faculty of Medicine, Ostrava University, Czech Republic.
  • Chen C; Cancer Clinical Research Unit, Princess Margaret Cancer Center, Toronto, ON, Canada.
  • Di Bacco A; Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Atlanta, GA, USA.
  • Estevam J; Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Atlanta, GA, USA.
  • Gupta N; Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Atlanta, GA, USA.
  • Byrne C; Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Atlanta, GA, USA.
  • Lu V; Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Atlanta, GA, USA.
  • van de Velde H; Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Atlanta, GA, USA.
  • Lonial S; Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Haematologica ; 103(9): 1518-1526, 2018 09.
Article en En | MEDLINE | ID: mdl-29954932

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Compuestos de Boro / Protocolos de Quimioterapia Combinada Antineoplásica / Glicina / Mieloma Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2018 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Compuestos de Boro / Protocolos de Quimioterapia Combinada Antineoplásica / Glicina / Mieloma Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2018 Tipo del documento: Article País de afiliación: España